VSTM · Verastem, Inc. · Financials
$7.32
-0.30 (-3.94%)
At close · Sep 11
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, given the risks associated with these potential strategic or financing opportunities, they are not deemed probable for purposes of the going concern assessment and do not alleviate the substantial doubt about our ability to continue as a going concern. There can be no assurance that we will be able to generate sufficient net product revenues or obtain additional capital on favorable terms or at all.”View the 10-Q filed Aug 6, 2026
Market Cap
$669.72M
Shares
90.56M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$30.91M
+209.1%
FY2025
Net Income
-$209.47M
-60.3%
FY2025
Gross Margin
99.38%
FY2018
Operating Margin
-550.33%
+599.2pp
FY2025
Diluted EPS
-$3.02
+17.5%
FY2025
Operating Cash Flow
-$137.51M
-31.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $30.91M | $10M | — | $2.6M | $2.05M | $88.52M | $17.46M | $26.72M | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $165K | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $26.55M | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | 99.38% | — | — | — | — | — | — | — | |
| $140.22M | $114.6M | $81.33M | $61.36M | $50.56M | $39.35M | $41.38M | $45.78M | $43.65M | $46.42M | $19.78M | $40.57M | $35.45M | $25.93M | $21.71M | $9.88M | |
| — | — | — | — | — | — | — | — | — | $21.38M | $17.22M | $17.63M | $18.16M | $15.47M | $10.52M | $3.82M | |
| $95.16M | $81.15M | $43.62M | $30.73M | $24.98M | $24.12M | $62.76M | $101.21M | $77.27M | $21.38M | $17.22M | — | — | — | — | — | |
| — | $698K | — | — | — | — | $793K | $1.57M | $423K | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | $670K | $754K | $427K | $236K | $207K | $83K | |
| — | — | — | — | — | $0 | $4.78M | — | — | — | — | — | — | — | — | — | |
| $137.08M | — | — | — | — | — | — | — | $121.5M | $67.8M | $37M | $58.2M | $53.61M | $41.4M | $32.23M | $13.7M | |
| $247.32M | $201.04M | $124.96M | $92.08M | $75.53M | $63.46M | $137.88M | $149.8M | $121.5M | $67.8M | — | — | — | — | — | — | |
| -$159.8M | -$170.13M | -$114.96M | -$92.08M | -$72.94M | -$61.41M | -$49.36M | -$132.34M | -$94.78M | -$67.8M | -$37M | -$58.2M | -$53.61M | -$41.4M | -$32.23M | -$13.7M | |
| — | -550.33% | -1149.56% | — | -2809.59% | -2991.18% | -55.76% | -758.14% | -354.75% | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | -$36.33M | -$57.45M | -$53.18M | -$41.17M | -$32.02M | -$13.62M | |
| $1.48M | $1.14M | $4.56M | $4.14M | $2.14M | $9.97M | $15.79M | $20.61M | $5.81M | $559K | — | — | — | — | — | — | |
| $4.69M | $4.07M | $4.15M | $6.21M | $1.22M | $181K | $515K | $4.38M | $2.6M | $561K | $562K | $334K | $242K | $200K | $246K | $15K | |
| -$166K | -$203K | -$123K | -$109K | $47K | — | -$1.31M | -$641K | $25.56M | — | — | — | — | — | — | — | |
| — | -$209.47M | -$130.45M | -$87.37M | -$73.81M | -$71.2M | -$67.53M | -$149.21M | -$72.43M | — | — | — | — | — | — | — | |
| — | — | $185K | — | $0 | $0 | $194K | $0 | $0 | — | — | — | — | — | — | — | |
| -$202.7M | -$209.47M | -$130.64M | -$87.37M | -$73.81M | -$71.2M | -$67.73M | -$149.21M | -$72.43M | -$67.8M | -$36.44M | -$57.87M | -$53.37M | -$41.2M | -$31.98M | -$13.68M | |
| — | -677.59% | -1306.37% | — | -2843.3% | -3468.1% | -76.51% | -854.77% | -271.11% | — | — | — | — | — | — | — | |
| -$41.15M | — | — | — | — | — | — | — | — | — | -$36.44M | -$57.87M | -$53.37M | -$41.2M | -$31.99M | -$13.72M | |
| -$202.64M | -$204.24M | -$130.65M | -$87.35M | -$73.85M | -$71.22M | -$67.69M | -$149.32M | -$72.31M | -$67.83M | -$36.45M | -$57.83M | -$53.38M | -$41.2M | -$31.96M | -$13.69M | |
| USD/shares | -$2.39 | -$3.02 | -$3.66 | -$3.96 | -$4.57 | -$4.90 | -$5.28 | -$24.00 | -$13.44 | -$21.12 | -$11.88 | — | — | — | — | — |
| USD/shares | -$2.25 | -$3.02 | -$3.66 | -$3.96 | -$4.57 | -$4.90 | -$5.28 | -$24.00 | -$16.44 | -$21.12 | -$11.88 | — | — | — | — | — |
| shares | — | 69.31M | 35.71M | 22.05M | 16.14M | 14.54M | 12.78M | 6.21M | 5.41M | 3.2M | 3.08M | 2.99M | 2.15M | 1.89M | 1.56M | 107.92K |
| shares | — | 69.31M | 35.71M | 22.05M | 16.14M | 14.54M | 12.78K | 6.21M | 5.78M | 3.2M | 3.08M | 2.99M | 2.15M | 1.89M | 1.56M | 107.92K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
7.10×
Peer median 6.45×
EV/EBIT
—
Peer median 11.00×
P/E (TTM)
—
Peer median 13.09×
Peer medians compare against the 307 similar-size Biotechnology companies (of 536 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2022 |
|---|---|---|---|
| Research Developing and Commercialization Drugs Segment | $30,914,000 | $10,000,000 | $2,596,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|
| Product | $30,914,000 | — | — | — | $15,232,000 | $12,339,000 | $1,718,000 |
| License | — | — | — | — | $2,912,000 | $5,117,000 | $25,000,000 |
| Copiktra License and Related Assets | — | $10,000,000 | $2,596,000 | $1,447,000 | $70,000,000 | — | — |
| Transition Services Revenue | — | — | — | $606,000 | $372,000 | — | — |
Key facts
CIK
1526119
CUSIP
92337C203
13F (30d)
88 filings
88 filers
Visit website
Investor relations